Group One Trading’s SpringWorks Therapeutics SWTX Stock Holding History

Group One Trading’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$1.41M	–	9124
2025 Q2	$1.41M	Sell	30,000 -3,600	-11%	-$160K	﹤0.01%	2446
2025 Q1	$1.48M	Buy	33,600 +11,800	+54%	+$543K	﹤0.01%	2095
2024 Q4	$788K	Buy	21,800 +16,200	+289%	+$566K	﹤0.01%	2783
2024 Q3	$179K	Hold	5,600	–	–	﹤0.01%	3722
2024 Q2	$211K	Buy	5,600 +4,200	+300%	+$177K	﹤0.01%	3344
2024 Q1	$68.9K	Sell	1,400 -24,700	-95%	-$1.14M	﹤0.01%	4439
2023 Q4	$953K	Buy	26,100 +22,900	+716%	+$598K	﹤0.01%	2496
2023 Q3	$74K	Hold	3,200	–	–	﹤0.01%	4736
2023 Q2	$83.9K	Buy	+3,200	New	+$84.1K	﹤0.01%	4784
2022 Q3	–	Sell	-900	Closed	-$22K	–	8235
2022 Q2	$22K	Sell	900 -17,300	-95%	-$633K	﹤0.01%	6227
2022 Q1	$1.03M	Buy	+18,200	New	+$1.04M	﹤0.01%	3042

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Group One Trading's SWTX Position: Q1 2025 in Review

Group One Trading sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 12,898 shares — an estimated $594K sold.

Group One Trading first reported a position in SWTX in Q2 2022 and held it in 7 quarters. The position peaked at $794K in Q1 2024. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

Group One Trading reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
Group One Trading sold 12,898 SpringWorks Therapeutics shares in Q1 2025, an estimated $594K.
Group One Trading first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 7 quarters.
Group One Trading's SpringWorks Therapeutics position peaked at $794K in Q1 2024.
306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.